Jill Siegfried

Q: What Schools Are Affiliated With Jill Siegfried

Jill Siegfried is affiliated with the following schools: Yale University, University of Oxford, University of Minnesota, University of California, San Diego, Wellesley College, Stanford University, University of Pittsburgh, University of California, San Francisco

Jill Siegfried's AcademicInfluence.com Rankings

Jill Siegfried

Medical

#3519

World Rank

#3990

Historical Rank

#521

USA Rank

Pharmacology

#450

World Rank

#505

Historical Rank

#42

USA Rank

medical Degrees

Download Badge

Medical

Jill Siegfried's Degrees

PhD Pharmacology University of California, San Francisco
Doctorate Medicine University of California, San Francisco

Why Is Jill Siegfried Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Jill M. Siegfried is an American pharmacologist. A Milwaukee, Wisconsin, native, Siegfried attended Wellesley College, where she received a double degree in German and molecular biology before earning advanced degrees in pharmacology from Yale University. Siegfried completed two years of postdoctoral study at the University of North Carolina, Chapel Hill prior to joining the faculty of University of Pittsburgh. Later, she was named University of Pittsburgh Medical Center Endowed Chair for Lung Cancer Research, a position she left in 2013 to accept an appointment at the University of Minnesota as Frederick and Alice Stark Professor of Pharmacology.

(See a Problem?)

Jill Siegfried's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Comprehensive molecular profiling of lung adenocarcinoma (2014) (4095)
Comprehensive genomic characterization of squamous cell lung cancers (2012) (2998)
Association of radiographic emphysema and airflow obstruction with lung cancer. (2008) (444)
Human Non-Small Cell Lung Tumors and Cells Derived from Normal Lung Express Both Estrogen Receptor α and β and Show Biological Responses to Estrogen (2002) (382)
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. (2005) (306)
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward (2006) (272)
Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. (2002) (266)
Expression of adrenomedullin in normal human lung and in pulmonary tumors. (1995) (220)
The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan. (2008) (204)
HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer (2009) (203)
Unlocking Biomarker Discovery: Large Scale Application of Aptamer Proteomic Technology for Early Detection of Lung Cancer (2010) (194)
Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. (2000) (184)
Genetic instability of microsatellite sequences in many non-small cell lung carcinomas. (1994) (179)
Detection of K-ras mutations in lung carcinomas: relationship to prognosis. (1996) (177)
Src Family Kinases Mediate Epidermal Growth Factor Receptor Ligand Cleavage, Proliferation, and Invasion of Head and Neck Cancer Cells (2004) (176)
Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. (1993) (174)
Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. (1997) (171)
Women and lung cancer: does oestrogen play a role? (2001) (165)
Comparative genomic hybridization analysis detects frequent, often high-level, overrepresentation of DNA sequences at 3q, 5p, 7p, and 8q in human non-small cell lung carcinomas. (1997) (162)
Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. (2005) (161)
Downregulation of Dkk3 activates β-catenin/TCF-4 signaling in lung cancer (2008) (154)
Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. (2006) (149)
Combined Analysis of Estrogen Receptor β-1 and Progesterone Receptor Expression Identifies Lung Cancer Patients with Poor Outcome (2010) (144)
Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. (2006) (140)
Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. (2006) (135)
Estrogen receptor signaling in lung cancer. (2009) (123)
Early Detection of Head and Neck Cancer: Development of a Novel Screening Tool Using Multiplexed Immunobead-Based Biomarker Profiling (2007) (122)
A mitogenic peptide amide encoded within the E peptide domain of the insulin-like growth factor IB prohormone. (1992) (119)
Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. (2011) (114)
Diagnostic Accuracy of MALDI Mass Spectrometric Analysis of Unfractionated Serum in Lung Cancer (2007) (112)
Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma (2008) (110)
HGF-independent Potentiation of EGFR Action by c-Met (2011) (110)
Optimal threshold in CT quantification of emphysema (2012) (110)
Cellular transport of anthracyclines by passive diffusion. Implications for drug resistance. (1985) (106)
Molecular Analysis of Plasma DNA for the Early Detection of Lung Cancer by Quantitative Methylation-Specific PCR (2010) (106)
Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer. (2008) (105)
Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells (2011) (105)
Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer. (1999) (103)
The clinical significance of hepatocyte growth factor for non-small cell lung cancer. (1998) (102)
Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. (1999) (102)
Anatomic segmentectomy for the solitary pulmonary nodule and early-stage lung cancer. (2012) (102)
Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells. (2007) (101)
Estrogen receptor pathways in lung cancer (2004) (100)
Fibulin-5 suppresses lung cancer invasion by inhibiting matrix metalloproteinase-7 expression. (2009) (98)
Estrogen receptor beta (ERβ) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells (2009) (95)
Estrongenic steroid hormones in lung cancer. (2014) (94)
Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer (2007) (89)
c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met (2012) (89)
Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry. (2010) (88)
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. (2009) (86)
Nicotine signals through muscle-type and neuronal nicotinic acetylcholine receptors in both human bronchial epithelial cells and airway fibroblasts (2004) (86)
Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor (2003) (85)
Chromosome abnormalities in human non-small cell lung cancer. (1992) (85)
Impact of tumor size on outcomes after anatomic lung resection for stage 1A non-small cell lung cancer based on the current staging system. (2012) (84)
Frequent Inactivation of RAMP2, EFEMP1 and Dutt1 in Lung Cancer by Promoter Hypermethylation (2007) (81)
Doubling times and CT screen–detected lung cancers in the Pittsburgh Lung Screening Study. (2012) (81)
Stimulatory effects of hepatocyte growth factor on normal and neoplastic human bronchial epithelial cells. (1995) (80)
Prognostic value of specific KRAS mutations in lung adenocarcinomas. (1997) (78)
Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma (2012) (75)
Chromosome alterations in 21 non‐small cell lung carcinomas (1990) (74)
Cross-Talk between Estrogen Receptor and Epidermal Growth Factor Receptor in Head and Neck Squamous Cell Carcinoma (2009) (74)
A Multiplexed Serum Biomarker Immunoassay Panel Discriminates Clinical Lung Cancer Patients from High-Risk Individuals Found to be Cancer-Free by CT Screening (2012) (73)
Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. (2002) (69)
Validation of a blood protein signature for non-small cell lung cancer (2014) (68)
Sex and gender differences in lung cancer. (2003) (66)
CT based computerized identification and analysis of human airways: a review. (2012) (62)
Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. (2005) (62)
Detection of micrometastases in histologically negative lymph nodes in esophageal cancer. (1998) (61)
Detection of human lung epithelial cell growth factors produced by a lung carcinoma cell line: use in culture of primary solid lung tumors. (1987) (61)
Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation (2017) (57)
Multiplexed Analysis of Serum Cytokines as Biomarkers in Squamous Cell Carcinoma of the Head and Neck Patients (2005) (55)
Comparison of p53 mutations between adenocarcinoma and squamous cell carcinoma of the lung: unique spectra involving G to A transitions and G to T transversions in both histologic types. (2003) (55)
Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer. (2003) (55)
Immunohistochemical Analysis of Phosphotyrosine Signal Transducer and Activator of Transcription 3 and Epidermal Growth Factor Receptor Autocrine Signaling Pathways in Head and Neck Cancers and Metastatic Lymph Nodes (2008) (54)
Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung Cancer (2012) (52)
Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib. (2007) (52)
Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond. (2006) (51)
The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma (2013) (50)
Effects of anthracyclines on oxygenated and hypoxic tumor cells. (1983) (50)
Expression of mRNA for gastrin-releasing peptide receptor by human bronchial epithelial cells. Association with prolonged tobacco exposure and responsiveness to bombesin-like peptides. (1997) (49)
Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells (2003) (47)
Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens. (2012) (47)
Expression of mRNA for three bombesin receptor subtypes in human bronchial epithelial cells. (1994) (46)
Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer (2018) (46)
Effects of bombesin and gastrin‐releasing peptide on human bronchial epithelial cells from a series of donors: Individual variation and modulation by bombesin analogs (1993) (46)
Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. (2005) (45)
Matrix metalloproteinase-19 promotes metastatic behavior in vitro and is associated with increased mortality in non-small cell lung cancer. (2014) (45)
Production of gastrin-releasing peptide by a non-small cell lung carcinoma cell line adapted to serum-free and growth factor-free conditions. (1994) (45)
Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers (2007) (44)
Comparison of anthracycline concentrations in S180 cell lines of varying sensitivity. (1983) (44)
Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis (2008) (43)
Signaling Pathways Involved in Cyclooxygenase-2 Induction by Hepatocyte Growth Factor in Non–Small-Cell Lung Cancer (2007) (43)
SULF2 Methylation is Prognostic for Lung Cancer Survival and Increases Sensitivity to Topoisomerase-I inhibitors via Induction of ISG15 (2011) (43)
Mutations in the arginine-rich protein gene, in lung, breast, and prostate cancers, and in squamous cell carcinoma of the head and neck. (1996) (42)
Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero‐digestive tract (2005) (42)
Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice (2010) (41)
Response of primary human lung carcinomas to autocrine growth factors produced by a lung carcinoma cell line. (1988) (41)
Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer (2014) (40)
Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer (2006) (40)
Evidence for the lack of relationship between inhibition of nucleic acid synthesis and cytotoxicity of adriamycin. (1983) (40)
Trinucleotide repeat length variation in the human ribosomal protein L14 gene (RPL14): localization to 3p21.3 and loss of heterozygosity in lung and oral cancers. (1998) (38)
Kinin B2 Receptor Mediates Induction of Cyclooxygenase-2 and Is Overexpressed in Head and Neck Squamous Cell Carcinomas (2008) (37)
Detection of infrequent and multiple K-ras mutations in human tumors and tumor-adjacent tissues. (1997) (35)
Lung Cancer Risk Prediction Using Common SNPs Located in GWAS-Identified Susceptibility Regions (2015) (35)
Lung Cancer Serum Biomarker Discovery Using Label-Free Liquid Chromatography-Tandem Mass Spectrometry (2011) (34)
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer (2017) (33)
Fluorescence bronchoscopic surveillance after curative surgical resection for non-small-cell lung cancer (2000) (33)
Epigenetic Repression of CCDC37 and MAP1B Links Chronic Obstructive Pulmonary Disease to Lung Cancer (2015) (32)
Multianalyte profiling of serum cytokines for detection of pancreatic cancer. (2005) (31)
Smoking Out Reproductive Hormone Actions in Lung Cancer (2014) (30)
Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. (2018) (30)
Topographic analysis of K-ras mutations in histologically normal lung tissues and tumours of lung cancer patients (2001) (29)
Familial aggregation of breast cancer with early onset lung cancer (1999) (28)
ATM protein is deficient in over 40% of lung adenocarcinomas (2016) (27)
STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non–Small Cell Lung Cancer (2018) (27)
Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer (2017) (27)
Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome12 (2015) (26)
RET Rearrangements in Lung Adenocarcinoma and Radiation (2014) (26)
Clinical relevance of chromosome abnormalities in non-small cell lung cancer. (1998) (26)
Lung Endothelial MicroRNA‐1 Regulates Tumor Growth and Angiogenesis (2017) (25)
Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer. (2013) (25)
Hormone replacement therapy and decreased lung cancer survival. (2006) (24)
Genetic determinants for promoter hypermethylation in the lungs of smokers: a candidate gene-based study. (2012) (24)
Serum biomarker profiles as diagnostic tools in lung cancer. (2011) (24)
Increased methylation of lung cancer-associated genes in sputum DNA of former smokers with chronic mucous hypersecretion (2014) (22)
Influence of age and IB status after resection of node-negative non-small cell lung cancer. (2012) (22)
Incidence of head and neck squamous cell carcinoma among subjects at high risk of lung cancer: Results from the Pittsburgh Lung Screening Study (2015) (22)
Alterations of human endometrial stromal cells produced by N-methyl-N'-nitro-N-nitrosoguanidine. (1983) (22)
K-ras mutations in lung tumors from NNK-treated mice with lipopolysaccharide-elicited lung inflammation. (2011) (21)
Characterization of a pure heterologous sarcoma of the uterus: rhabdomyosarcoma of the corpus. (1983) (21)
Monolayer culture of human endometrium: Methods of culture and identification of cell types (1982) (21)
Alpha-amidation of peptide hormones in lung cancer. (1991) (21)
Association of the EGFR intron 1 CA repeat length with lung cancer risk (2007) (21)
Detection of Occult Lymph Node Metastases in Esophageal Cancer by Minimally Invasive Staging Combined with Molecular Diagnostic Techniques (1998) (21)
KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients (2017) (20)
Automated Lobe-Based Airway Labeling (2012) (20)
Culture of primary lung tumors using medium conditioned by a lung carcinoma cell line (1989) (19)
Biology and chemoprevention of lung cancer. (1998) (19)
Flow cytometric analysis of human uterine sarcomas and cell lines. (1987) (19)
Computerized identification of airway wall in CT examinations using a 3D active surface evolution approach (2013) (18)
NF-κB1 p105 suppresses lung tumorigenesis through the Tpl2 kinase but independently of its NF-κB function (2015) (18)
Elevated hepatocyte growth factor level correlates with poor outcome in early-stage and late-stage adenocarcinoma of the lung. (2004) (18)
Role of NQO1 polymorphisms as risk factors for squamous cell carcinoma of the head and neck. (2005) (18)
Characterization of 9q;15q whole-arm translocation derivatives in non-small cell lung carcinomas by fluorescence in situ hybridization. (1993) (18)
Correlation of model chromosome number of cultured non-small cell lung carcinomas with DNA index of solid tumor tissue. (1991) (18)
Illustration of the obstacles in computerized lung segmentation using examples. (2012) (17)
Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco‐Induced Lung Cancer (2017) (17)
15q12 variants, sputum gene promoter hypermethylation, and lung cancer risk: a GWAS in smokers. (2015) (17)
Activity of anti-erbB-2 recombinant toxin OLX-209 on lung cancer cell lines in the absence of erbB-2 gene amplification. (1996) (17)
Metabolism of benzo(a)pyrene in monolayer cultures of human bronchial epithelial cells from a series of donors. (1986) (16)
Cytotoxicity of chemical carcinogens towards human bronchial epithelial cells evaluated in a clonal assay. (1984) (16)
Early Changes in Pulmonary Gene Expression following Tobacco Exposure Shed Light on the Role of Estrogen Metabolism in Lung Carcinogenesis (2010) (16)
Lung Adenocarcinoma Syndecan-2 Potentiates Cell Invasiveness. (2019) (16)
Novel targets for lung cancer therapy (2006) (15)
Three-dimensional airway tree architecture and pulmonary function. (2012) (15)
Combination therapy with gefitinib and fulvestrant (G/F) for women with non-small cell lung cancer (NSCLC) (2005) (15)
Early events in the neoplastic transformation of respiratory epithelium. (1992) (15)
Sex-specific association of sequence variants in CBS and MTRR with risk for promoter hypermethylation in the lung epithelium of smokers. (2012) (14)
The heterogeneity of LDH isoenzyme patterns of human uterine sarcomas and cultured sarcoma cell lines. (1984) (14)
Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment (2014) (14)
Comparison of Mutations in the p 53 and Kras Genes in Lung Carcinomas from Smoking and Nonsmoking Women 1 (1999) (13)
Multiple Cytokine and Growth Factor Serum Biomarkers Predict Therapeutic Response and Survival in Advanced-Stage Head and Neck Cancer Patients (2007) (13)
Promotional effect of diethylstilbestrol on human endometrial stromal cells pretreated with a direct-acting carcinogen. (1984) (13)
Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma (2015) (12)
Transfection of a Rat Cytochrome P450b cDNA Into C3H10T1/2CL8 Mouse Embryo Fibroblasts (1989) (12)
Combined Inhibition of cSrc and Epidermal Growth Factor ReceptorAbrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma (2008) (11)
Gene methylation biomarkers in sputum as a classifier for lung cancer risk. (2017) (11)
Transfer and expression of the human interleukin-4 gene in carcinoma and stromal cell lines derived from lung cancer patients. (1993) (11)
Hepatocyte growth factor promotes tumor growth in a novel in vivo model of human lung cancer. (2001) (11)
Morphology and growth potential of stromal cell cultures derived from human endometrium (1982) (11)
Identification of pulmonary fissures using a piecewise plane fitting algorithm (2012) (10)
Gene Promoter Hypermethylation Detected in Sputum Predicts FEV1 Decline and All‐Cause Mortality in Smokers (2018) (10)
Detection of Kras Mutations in Lung Carcinomas : Relationship to Prognosis 1 (2008) (10)
Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study (2012) (10)
Interim safety analysis of a phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC) (2008) (9)
Abstract 4664: Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC). (2013) (9)
Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer (2017) (8)
Inhibiting pathways predicted from a steroid hormone gene signature yields synergistic anti-tumor effects in non-small cell lung cancer. (2019) (7)
Effect of phorbol esters on clonal cultures of human, hamster, and rat respiratory epithelial cells. (1987) (7)
Histochemical identification of cultured cells from human endometrium (2007) (7)
Genetic variation in ESR2 and estrogen receptor-beta expression in lung tumors. (2013) (7)
Anatomic Lung Resection for Clinical Stage I Non-small Cell Lung Cancer (NSCLC): Equivalent Outcomes Following Anatomic Segmentectomy and Lobectomy (2010) (6)
Cells cultured from non-small cell lung carcinomas are representative of solid tumor tissue based on cytogenetic evidence (1991) (6)
Inherited Variation in the ATP-Binding Cassette Transporter ABCB1 and Survival after Chemotherapy for Stage III–IV Lung Cancer (2014) (6)
Secretion of autocrine growth factors by cultured human lung tumors: Effects on neoplastic lung epithelial cells (1988) (6)
Correction: c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met (2013) (6)
Randomized phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC). (2010) (5)
Gene methylation biomarkers in sputum as a classifier for lung cancer risk (2017) (5)
Transfection of cytochrome P450 cDNAs into mammalian cells used in mutation and transformation assays. (1990) (5)
Sex and Gender Differences in Lung Cancer and Chronic Obstructive Lung Disease. (2021) (5)
Robust pulmonary lobe segmentation against incomplete fissures (2012) (5)
Co-targeting c-Met and COX-2 Leads to Enhanced Inhibition of Lung Tumorigenesis in a Murine Model with Heightened Airway HGF (2014) (5)
Analysis of isoenzymes in normal and carcinogen-treated human endometrial stromal cells in culture. (1985) (5)
Enhancement by TPA of phenotypes associated with transformation in carcinogen‐treated human cells: Evidence for a selective mechanism (1983) (4)
Prevention of Tobacco Carcinogen-Induced Lung Tumor Development by a Novel STAT3 Decoy Inhibitor (2020) (4)
Lung cancer screening in high-risk populations. (1999) (4)
Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T-cell Mediated Anti-Tumor Response and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression. (2020) (4)
Induction of micronuclei in cultured human bronchial epithelial cells by direct-acting carcinogens. (1990) (4)
Imaging , Diagnosis , Prognosis Combined Analysis of Estrogen Receptor b-1 and Progesterone Receptor Expression Identifies Lung Cancer Patients with Poor Outcome (2010) (4)
Ability to culture resectable non-small cell lung carcinomas is correlated with recurrence. (1994) (4)
Abstract 4564: Lung cancer serum biomarker discovery using label free LC-MS/MS (2010) (3)
Genes for tumor markers are clustered with cellular proto-oncogenes on human chromosomes. (1987) (3)
Neoadjuvant erlotinib, erlotinib-sulindac, or placebo: A randomized, double-blind biomarker modulation study in operable head and neck squamous cell carcinoma (HNSCC). (2013) (3)
Abstract 3864: Biological basis of pan-ErbB receptor targeting for malignant melanoma treatment (2012) (3)
Exposing the criminal record of every blood sample: Use of SOMAmer technology and sample mapping vectors to mitigate false biomarker discoveries in lung cancer. (2012) (3)
No association between the XPD 312, 751, or XRCC1 399 polymorphisms and K-ras gene mutation in smoking non-small-cell lung cancer. (2004) (3)
Gender-Related Differences in Lung Cancer (2018) (3)
PD-071 Combination therapy with gefitinib and fulvestrant (G/F) forwomen with non-small cell lung cancer (NSCLC) (2005) (3)
Investigation of adriamycin resistant cell lines with respect to proposed mechanisms of drug action. Abstr. (1980) (3)
Heterogeneity in responses of human and rodent respiratory epithelial cells to tumor promoters in culture. (1985) (2)
The HER2 tyrosine kinase is a direct target of erlotinib (Tarceva™), a potent inhibitor of EGFR/HER1 kinase. (2004) (2)
Abstract 4101: Targeting the EGFR/STAT3 axis in NSCLC with resistance to EGFR tyrosine kinase inhibitors using an oligonucleotide-based decoy (2017) (2)
Prostaglandin E2 and Bradykinin contribute to head and neck squamous cell carcinoma carcinogenesis via EGFR dependent and independent mechanisms. (2005) (2)
Toxicity of anthracyclines toward normally aerated and hypoxic tumor cells (1981) (2)
Abstract B20: Prediction of lung cancer survival by genes in the PAM50 breast cancer panel. (2014) (2)
Endometrial stromal cells in culture: an attempt to understand the genesis and biologic activity of uterine sarcomas. (1986) (2)
Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting (2021) (2)
Targeting the ERβ/HER Oncogenic Network in KRAS Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy (2021) (2)
Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T cell Mediated Anti-Tumor Response and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression (2020) (2)
Abstract 4377: Pulmonary inflammation and lung tumorigenesis in mice (2010) (1)
Targeting the estrogen receptor for lung cancer therapy (2005) (1)
ASSOCIATION FOR ACADEMIC SURGERY Increased Levels of Tumor-Infiltrating Lymphocytes are Associated with Improved Recurrence-Free Survival in Stage 1A Non-Small-Cell Lung Cancer (2011) (1)
HGF Airway Over-expression Leads to Enhanced Pulmonary Vascularization without Induction of VEGF. (2012) (1)
Abstract 14: Identification of probands with multiple mutations in cancer susceptibility genes using a multigene panel approach (2014) (1)
A prospective and retrospective analysis of smoking behavior changes in ever smokers with high risk for lung cancer from New Mexico and Pennsylvania. (2016) (1)
Prediction of NSCLC Survival With the PAM50 Breast Cancer Signature (2014) (1)
Abstract 1027: Inhibiting pathways predicted from a steroid hormone gene signature yields synergistic antitumor effects in lung cancer (2019) (1)
High Levels Of Tumor-infiltrating Lymphocytes And The Absence Of Angiolymphatic Invasion Increase Recurrence-free Survival In Stage 1A Non-Small Cell Lung Cancer (2011) (1)
Biomarker Discovery and Verification of a Lung Cancer Signature with SOMAmer Proteomic Technology (2012) (1)
Null Results in Brief No Association between the XPD 312 , 751 , or XRCC 1 399 Polymorphisms and Kras Gene Mutation in Smoking Non-Small-Cell Lung Cancer (2004) (1)
Use of ERCC1 polymorphism and extreme drug resistance assay to predict overall non-small cell lung cancer survival and responsiveness to platinum-based chemotherapy agents (2008) (1)
Strategies for identification of peptide growth factors. (1992) (1)
Factors influencing recurrence following anatomic lung resection for non-small cell lung cancer. (2012) (1)
Kinin B 2 Receptor Mediates Induction of Cyclooxygenase-2 and Is Overexpressed in Head and Neck Squamous Cell Carcinomas (2008) (1)
Abstract 4123: Induction of motility, invasion, and proliferation by wild-type EGFR depends on c-Met in NSCLC (2010) (1)
Gastrin-releasing peptide receptor upregulation in human lung adenocarcinoma (2007) (0)
For Peer Review Prevention of Tobacco Carcinogen-Induced Lung Cancer in Female Mice Using Anti-Estrogens (2012) (0)
Abstract 608: Targeting the estrogen pathway in a male mouse model of lung tumor prevention (2014) (0)
Cancer Therapy : Preclinical cSrc Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met (2013) (0)
Implications Of A Normal Initial Computed Tomography (CT) Scan For Lung Cancer Screening (2012) (0)
Modulation of calyculin a-induced apoptosis in lung cancer cells by serum and cell density (1996) (0)
Abstract 3461: C-kit inhibitors and radiation: A promising combination in NSCLC (2012) (0)
Promotion by TPA of preneoplastic changes in human endometrial stromal cells (1982) (0)
Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma (2015) (0)
Abstract LB-414: Variation in base excision repair genes and risk of smoking-related non-small cell lung cancer (2010) (0)
K-ras and p53 genes mutations and polymorphisms of the DNA repair XPD and XRCC1 genes in lung cancer among smokers and nonsmokers (2004) (0)
E57. Estrogen receptor epidermal growth factor receptor interactions in lung cancer (2005) (0)
Abstract 2026: Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened HGF signaling in the airways. (2013) (0)
A Peripheral Blood Biomarker Signature Potentially Identifies Smokers with Interstitial Lung Abnormalities (2013) (0)
Early natural menopause is associated with poor lung health and increased mortality among female smokers. (2022) (0)
Comparison of response to growth factors between normal and neoplastic human bronchial epithelial cells (1985) (0)
The Impact of Microscopically Positive Final Pathologic Margins Identified Days After Surgery in Resected Non-small Cell Lung Cancer (NSCLC) (2013) (0)
Abstract PR04: Distinctive squamous cell carcinoma protein signatures. (2014) (0)
Production of growth factors by non-small-cell lung carcinomas (1992) (0)
Studies on the effects of adriamycin (adr) and daunomycin (dnr) on oxygenated and hypoxic tumor cells in vitro. Abstr. (1980) (0)
Promotion-like enhancement of transformed phenotypes in human endometrial stromal cells. (1985) (0)
Has the paradigm changed away from lobectomy for stage I non-small cell lung cancer (NSCLC)? Anatomic segmentectomy: Surgery’s answer to image-guided ablation/radiation therapy for the small peripheral lung lesion. (2013) (0)
Abstract 2181: Differential expression of genes related to autoimmunity and metabolism in Stage I NSCLC from patients with COPD (2015) (0)
Nicotine promotes survival of NSCLC cells in the presence of anti-tumor agents (2005) (0)
The Hilar Stage IB-IIB Non-small Cell Lung Cancer: Differential Morbidity, Mortality, and Outcomes Between Lobectomy and Pneumonectomy (2012) (0)
Evidence of Vegf downregulation in carcinogen-induced lung tumors from transgenic mice overexpressing human HGF in the small airways (2007) (0)
Abstract A39: Prevention of tobacco carcinogen-induced lung cancer in mice using antiestrogens (2012) (0)
Human Cancer Biology Cross-Talk between Estrogen Receptor and Epidermal Growth Factor Receptor in Head and Neck Squamous Cell Carcinoma (2009) (0)
Flow Cytometric Analysis of Human Uterine Sarcomas and Cell Lines1 (2006) (0)
Validation of a blood protein signature for non-small cell lung cancer (2014) (0)
Evidence for a tumor suppressor gene on chromosome 3 in human non-small cell lung carcinoma (1995) (0)
Prognosis Tumor Epidermal Growth Factor Receptor and EGFRPY 1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma (2012) (0)
E-73.Hormones - do they make a difference in lung cancer? (2003) (0)
Abstract 3667: ERβ and PR expression show opposite effects on survival in NSCLC with no sex differences (2010) (0)
Abstract 3875: A novel STAT3 decoy inhibitor prevents lung cancer development (2019) (0)
729. C-Met Antisense Plasmid Liposome Complex Increases Radiation Sensitivity of Lung Tumor Cells In Vivo or In Vitro (2005) (0)
Anatomic segmentectomy versus lobectomy for clinical stage I non-small cell lung cancer: A propensity-matched analysis. (2012) (0)
Enrichment of Met Amplification and Kras Mutations in Non-Small Cell Lung Carcinoma (NSCLC) Brain Metastases (2014) (0)
Targeting of the Hepatocyte Growth Factor Pathway for the Treatment of Breast Cancer (2000) (0)
Abstract LB-210: A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from cancer-free high-risk subjects in a CT-screened cohort (2010) (0)
The HGF/c-Met pathway activates COX-2 in non-small cell lung cancer (2006) (0)
GROWTH FACTORS AND RECEPTORS IN NON-SMALL CELL LUNG CANCER (1998) (0)
Association of high circulating neuregulin-1 with clinical benefit in EGFR wild-type NSCLC patients treated with rilotumumab and erlotinib. (2016) (0)
Variation in the EGFR gene is associated with lung cancer (2005) (0)
Abstract LB-180: Prevention of NNK-induced lung cancer in mice by anti-estrogen therapy (2010) (0)
Increased sensitivity of carcinogen-treated human endometrial cells to morphological changes induced by TPA (1981) (0)
Abstract 1722: Prognostic markers in early stage non small-cell lung cancer (NSCLC) (2012) (0)
Abstract B24: Untangling the interplay of lung cancer biomarkers and preanalytic variability with SOMAmer proteomic technology (2012) (0)
Detection of c-K-ras point mutations in human lung tumors by denaturing gradient gel electrophoresis (1995) (0)
Abstract 4937: Factors in NSCLC stage and outcome: Integrated genome-wide study (2012) (0)
P72.07 Modulation of the Tumor Microenvironment by Targeting ERb/HER Oncogenic Network in Lung Cancer Produces Synergy when Followed by Immunotherapy (2021) (0)
Abstract 1861: Estrogen modulation of fibroblast growth factor signaling in non-small cell lung cancer (2015) (0)
Abstract 1005: Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer (2017) (0)
Abstract 2349: Modulation of inflammation in the tumor microenvironment by ER and PPARγ in an NNK-induced lung carcinogenesis model (2019) (0)
Correction: HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer (2010) (0)
Abstract 4661: Decreased epidermal growth factor receptor plasma levels as an indicator for head and neck squamous cell carcinoma case status and disease progression (2010) (0)
Abstract 3261: Gene methylation biomarkers in sputum as a classifier for lung cancer risk (2017) (0)
Comprehensivegenomiccharacterization of squamous cell lung cancers (2012) (0)
P-238 Two-year outcomes from lung cancer screening with low-dose helical computed tomography (2005) (0)
Serum biomarkers for early detection of lung cancer. (2010) (0)
Abstract 1720: Validation of a 15-gene prognostic signature in stage IB non small-cell lung cancer (NSCLC) (2012) (0)
Abstract 3483: Combining the multi-targeted tyrosine kinase inhibitor, vandetanib, with fulvestrant results in enhanced anti-tumorigenic effects for lung cancer (2010) (0)
Gastrin-Releasing Peptide Receptor Mediates Activation of the Epidermal Growth Factor Receptor in Lung Cancer Cells 1 (2005) (0)
Abstract A019: Targeting STAT3 for lung cancer prevention (2022) (0)
Carcinomas with DNA Index of Solid Tumor Tissue1 (2006) (0)

This paper list is powered by the following services:

Other Resources About Jill Siegfried

en.wikipedia.org

What Schools Are Affiliated With Jill Siegfried?

Jill Siegfried is affiliated with the following schools:

Jill Siegfried's Academic­Influence.com Rankings